Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
43 hedge funds and large institutions have $312M invested in Evelo Biosciences, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 43 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$266M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$48.3M |
| 3 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$25.7M |
| 4 |
AI
Alphabet Inc
Mountain View,
California
|
+$15.5M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$6.42M |
Top Sellers
EVLO Hedge Fund Activity: Q2 2018 in Review
43 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q2 2018, worth a combined $312M.
Buyers outnumbered sellers: 43 funds opened new EVLO positions and 0 closed out — a net gain of 43 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Flagship Pioneering, opening a new position worth an estimated $266M.
- 43 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $312M of Evelo Biosciences, Inc. Common Stock stock for Q2 2018.
- 43 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q2 2018 and 0 closed out, a net change of +43 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q2 2018 was Flagship Pioneering, an estimated $266M added.
Based on aggregated 13F filings for Q2 2018.